Ayupa.Ax
AYUPA.AX is a biotechnology company operating in the healthcare facilities and services industry, primarily generating revenue through its biotechnology operations.
Business. AYUPA.AX is a biotechnology company operating within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models typical of the healthcare services sector. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment breakdowns.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
AYUPA.AX is a biotechnology company operating within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models typical of the healthcare services sector. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment breakdowns.
AYUPA.AX has a market capitalization of $426.996 million and a price-to-earnings ratio of 16.08, indicating a moderate valuation relative to its earnings. The company's price-to-book ratio is 0.34, suggesting that the market values the company at a discount to its book value. The liquidity position is characterized by $507.736 million in cash and equivalents, but the company has $673.758 million in long-term debt, resulting in a net cash position that is negative after subtracting total debt.
In terms of profitability, AYUPA.AX has a return on equity (ROE) of 2.14% and a return on assets (ROA) of 0.25%, which are below the industry median for biotechnology firms. The company's operating income of $188.163 million and net income of $26.561 million indicate a profitable operation, but the ROE and ROA figures suggest that the company is not generating strong returns relative to its equity and asset base.
The company's revenue is concentrated in its biotechnology segment, with no significant geographic diversification disclosed in the available data. This concentration may expose the company to higher risk if the biotechnology segment faces regulatory or market challenges.
AYUPA.AX has demonstrated a growth trajectory with a positive operating cash flow of $106.464 million and a capital expenditure of -$83.58 million, indicating that the company is investing in its operations. The outlook for the current fiscal year suggests continued investment, with the potential for future growth depending on the success of these investments.
The risk assessment for AYUPA.AX indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations without additional financing. The dilution risk is low, suggesting that the company is not expected to issue a significant number of new shares in the near term.
Recent events, as disclosed in the latest financial filings, include the company's continued investment in its biotechnology operations and the maintenance of a strong cash position despite the negative net cash after debt. These events suggest a focus on long-term growth and operational stability.
- AYUPA.AX has a moderate valuation with a price-to-earnings ratio of 16.08 and a price-to-book ratio of 0.34.
- The company's return on equity and return on assets are below the industry median, indicating suboptimal returns relative to its equity and asset base.
- AYUPA.AX's revenue is concentrated in its biotechnology segment, with no significant geographic diversification.
- The company has a positive operating cash flow and is investing in its operations, suggesting a focus on long-term growth.
- The company faces medium liquidity risk and low dilution risk, with a negative net cash position after subtracting total debt.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- AYUPA.AX Market data — financials · 2026-05-27